Natera executive sells 3,405 shares under 10b5-1

Natera, Inc. executive Solomon Moshkevich, President of Clinical Diagnostics, sold a total of 3,405 shares of common stock on May 1, 2026 in multiple open-market transactions, at prices around $200–$207 per share.

Rhea-AI Filing Summary

Natera, Inc. executive Solomon Moshkevich, President of Clinical Diagnostics, sold a total of 3,405 shares of common stock on May 1, 2026 in multiple open-market transactions, at prices around $200–$207 per share.

According to the disclosures, part of the sale was made to satisfy tax withholding and remittance obligations tied to the vesting of restricted stock units, under written instructions intended to meet Rule 10b5-1(c) conditions. Additional shares were sold under a separate Rule 10b5-1 trading plan adopted on November 26, 2024. After these transactions, he directly holds 142,295 shares of Natera common stock.

Insider Trade Summary 10b5-1

Net Seller: 3,405 shares

Net Sell 7 txns

Insider Moshkevich Solomon

Role PRESIDENT, CLINICALDIAGNOSTICS

Sold 3,405 shs ($694K)

Type	Security	Shares	Price	Value
Sale	Common Stock	405	$206.16	$83K
Sale	Common Stock	560	$200.9523	$113K
Sale	Common Stock	520	$201.6004	$105K
Sale	Common Stock	505	$203.3155	$103K
Sale	Common Stock	865	$204.4657	$177K
Sale	Common Stock	400	$205.3075	$82K
Sale	Common Stock	150	$206.93	$31K

Holdings After Transaction: Common Stock — 142,295 shares (Direct)

Footnotes (7)

1. F1. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
2. F2. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.31 to $201.23 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.5200 to $20.6150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.00 to $203.81 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. F6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.17 to $205.05 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. F7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.19 to $205.56 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 3,405 shares Price per share (max reported): $206.93 per share Price per share (example): $205.3075 per share +4 more

7 metrics

Shares sold 3,405 shares Open-market sales on May 1, 2026

Price per share (max reported) $206.93 per share One of several May 1, 2026 sale prices

Price per share (example) $205.3075 per share Reported weighted average for one sale block

Price per share (example) $200.9523 per share Reported weighted average for another sale block

Shares held after transactions 142,295 shares Direct ownership following May 1, 2026 sales

Rule 10b5-1 plan adoption date November 26, 2024 Adoption date for trading plan used for some sales

Stock unit agreement grant date January 31, 2025 Grant date for RSU agreement referenced for tax sales

Key Terms

Rule 10b5-1 trading plan, Rule 10b5-1(c), RSUs, weighted average price, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Rule 10b5-1(c) regulatory

"written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

RSUs financial

"satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

weighted average price financial

"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding financial

"sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs"

Tax withholding is the practice of taking a portion of a payment—such as wages, dividends, or sale proceeds—before it reaches the recipient and sending that portion to the tax authority as an advance on the recipient’s eventual tax bill. For investors it matters because withholding reduces immediate cash received and affects after‑tax returns, estimated tax payments, and whether you may owe more or receive a refund when taxes are finally calculated, like having a small automatic savings set aside for your tax bill.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Natera (NTRA) report for Solomon Moshkevich?

Natera reported that executive Solomon Moshkevich sold 3,405 shares of common stock on May 1, 2026. The sales were executed in multiple open-market transactions at prices around $200–$207 per share, reflecting a relatively small portion of his overall direct holdings.

Why did Natera executive Solomon Moshkevich sell 3,405 NTRA shares?

A portion of the shares was sold to satisfy tax withholding and remittance obligations arising from the vesting of restricted stock units. The sales followed written instructions intended to meet Rule 10b5-1(c) conditions, alongside a pre-established Rule 10b5-1 trading plan for additional transactions.

How many Natera (NTRA) shares does Solomon Moshkevich hold after the reported sale?

After the May 1, 2026 transactions, Solomon Moshkevich directly holds 142,295 shares of Natera common stock. This figure reflects his position following the sale of 3,405 shares in multiple open-market trades disclosed in the Form 4 insider transaction report.

Were Solomon Moshkevich’s Natera (NTRA) share sales under a Rule 10b5-1 plan?

Yes. The disclosures state that some sales were effected pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024. In addition, tax-related sales followed written instructions intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

What prices did Natera (NTRA) executive shares sell for in the May 1, 2026 trades?

The reported transactions show sales prices generally around $200–$207 per share. Individual weighted average prices included $206.93, $205.3075 and $200.9523 per share, with additional sales at nearby levels, all executed as open-market transactions in Natera common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/05/2026 - 09:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moshkevich Solomon

(Last) (First) (Middle)

C/O NATERA, INC.

13011 MCCALLEN PASS BUILDING A SUITE 100

(Street)

AUSTIN TEXAS 78753

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Natera, Inc. [ NTRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CLINICALDIAGNOSTICS

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		S		405(1)	D	$206.16	145,295	D
Common Stock	05/01/2026		S		560(2)	D	$200.9523(3)	144,735	D
Common Stock	05/01/2026		S		520(2)	D	$201.6004(4)	144,215	D
Common Stock	05/01/2026		S		505(2)	D	$203.3155(5)	143,710	D
Common Stock	05/01/2026		S		865(2)	D	$204.4657(6)	142,845	D
Common Stock	05/01/2026		S		400(2)	D	$205.3075(7)	142,445	D
Common Stock	05/01/2026		S		150(2)	D	$206.93	142,295	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.

2. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.31 to $201.23 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.5200 to $20.6150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.00 to $203.81 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.17 to $205.05 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.19 to $205.56 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Tami Chen, Attorney-in-Fact	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)